Studies of Prostaglandin E Formation in Human Monocytes

Total Page:16

File Type:pdf, Size:1020Kb

Studies of Prostaglandin E Formation in Human Monocytes Faculty of Technology and Science Biomedical Sciences Sofia Karlsson Studies of prostaglandin E2 formation in human monocytes Karlstad University Studies 2009:43 Sofia Karlsson Studies of prostaglandin E2 formation in human monocytes Karlstad University Studies 2009:43 Sofia Karlsson Studies of prostaglandin E2 formation in human monocytes Licentiate thesis Karlstad University Studies 2009:43 ISSN 1403-8099 ISBN 978-91-7063-266-2 © The Author Distribution: Faculty of Technology and Science Biomedical Sciences SE-651 88 Karlstad +46 54 700 10 00 www.kau.se Printed at: Universitetstryckeriet, Karlstad 2009 ABSTRACT Prostaglandin (PG) E 2 is an eicosanoid derived from the polyunsaturated twenty carbon fatty acid arachidonic acid (AA). PGE 2 has physiological as well as pathophysiological functions and is known to be a key mediator of inflammatory responses. Formation of PGE 2 is dependent upon the activities of three specific enzymes involved in the AA cascade; phospholipase A 2 (PLA 2), cyclooxygenase (COX) and PGE synthase (PGEs). Although the research within this field has been intense for decades, the regulatory mechanisms concerning the PGE 2 synthesising enzymes are not completely established. PGE 2 was investigated in human monocytes with or without lipopolysaccharide (LPS) pre-treatment followed by stimulation with calcium ionophore, opsonised zymosan or phorbol myristate acetate (PMA). Cytosolic PLA 2α (cPLA 2α) was shown to be pivotal for the mobilization of AA and subsequent formation of PGE 2. Although COX-1 was constitutively expressed, monocytes required expression of COX-2 protein in order to convert the mobilized AA into PGH 2. The conversion of PGH 2 to the final product PGE 2 was to a large extent due to the action of microsomal PGEs-1 (mPGEs-1). In addition, experiments with inhibitors of extracellular signal regulated kinase and p38 activation, indicated that phosphorylation of cPLA 2α was markedly advantageous for the formation of PGE 2. Ellagic acid, a natural polyphenolic compound found in fruits and nuts, was shown to inhibit stimuli induced release of PGE2 in human monocytes. The effect of ellagic acid was not due to a direct effect on the activities of the enzymes but rather to inhibition of the LPS-induced protein expression of COX-2, mPGEs-1 and cPLA 2α. i LIST OF PUBLICATIONS This thesis is based on the following papers, which will be referred to in the text by their Roman numerals I. Karlsson, S . and Wijkander, J. Requirement of cyclooxygenase-2 expression for cytosolic phospholipase A 2 mediated prostaglandin E 2 formation in human monocytes. Manuscript II Karlsson, S ., Nånberg, E., Fjaeraa, C. and Wijkander, J. (2009) Ellagic acid inhibits lipopolysaccharide-induced expression of enzymes involved in the synthesis of prostaglandin E 2 in human monocytes. British Journal of Nutrition. Accepted. Grant Support : This study was supported by grants from Värmland County Council and the Royal Swedish Academy of Sciences. ii ABBREVIATIONS AA Arachidonic acid [3H]AA Tritiated arachidonic acid AP Activating protein BEL Bromoenol lactone CBR Calcium binding regions COX Cyclooxygenase cPGEs Cytosolic prostaglandin E synthase cPLA 2 Cytosolic phospholipase A 2 Egr-1 Early growth response factor -1 ERK Extracellular signal-regulated kinase GRE Glucocorticoid response element HETE Hydroxyeicosatetraenoic acid HPETE Hydroperoxyeicosatetraenoic acid IL Interleukin iPLA 2 Calcium independent phospholipase A 2 IκB Inhibitor kappa B LO Lipoxygenase LPS Lipopolysaccharide LT Leukotriene MAPK Mitogene activated protein kinase mPGEs Microsomal prostaglandin E synthase NF κB Nuclear factor kappa B NSAIDs Non-steroidal anti-inflammatory drugs PG Prostaglandin PGEs Prostaglandin E synthase PIP2 Phosphatidylinositol 4,5-bisphosphate PKC Protein kinase C PC Phosphatidylcholine PLA 2 Phospholipase A 2 PMA Phorbol myristate acetate sn Stereospecific nomenclature sPLA 2 Secretory phospholipase A 2 TNF α Tumor necrosis factor alfa TX Thromboxane iii TABLE OF CONTENTS ABSTRACT..................................................................................................i LIST OF PUBLICATIONS .......................................................................ii ABBREVIATIONS ...................................................................................iii TABLE OF CONTENTS .........................................................................iv INTRODUCTION..................................................................................... 1 Monocytes and their role in inflammation............................................. 1 Arachidonic acid and eicosanoids.......................................................... 2 From phospholipids to the final product prostaglandin E 2 ................... 2 Phospholipase A 2 .................................................................................... 3 Intracellular phospholipase A 2 ..............................................................................4 Cytosolic phospholipase A 2 .............................................................................4 Calcium independent phospholipase A 2 .......................................................6 Secretory phospholipase A 2 ...................................................................................7 Cyclooxygenases ..................................................................................... 8 Cyclooxygenase-1.....................................................................................................9 Cyclooxygenase-2...................................................................................................10 Cyclooxygenase-3...................................................................................................10 Differences between cyclooxygenase-1 and cyclooxygenase-2....................11 Cyclooxygenase inhibitors ...................................................................................12 Prostaglandin E synthases.................................................................... 12 Microsomal prostaglandin E synthase-1...........................................................13 Microsomal prostaglandin E synthase-2...........................................................14 Cytosolic prostaglandin E synthase ...................................................................14 Prostaglandin E 2 ................................................................................... 15 PRESENT INVESTIGATION ............................................................... 17 Background and aim............................................................................. 17 Methodology ......................................................................................... 19 Results and discussion.......................................................................... 22 Conclusions........................................................................................... 31 ACKNOWLEDGEMENTS ..................................................................... 32 REFERENCES ........................................................................................ 33 iv INTRODUCTION Monocytes and their role in inflammation Inflammation is an important part of our defence against pathological agents that we more or less are constantly exposed to. The inflammatory response is dependent on the production of different cytokines, chemokines and eicosanoids [1-3]. These inflammatory mediators are produced in a tightly regulated way primarily in white blood cells, leukocytes. Monocytes are large leukocytes of the myeloid lineage, circulating in the peripheral bloodstream. Upon activation, due to infection or mechanically damaged tissue, the monocytes migrate to the site of inflammation, penetrate the arterial wall and enter the surrounding tissue where they may differentiate into long-lived macrophages or dendritic cells [4]. Once at the infected area, monocytes act as professional phagocytes and recognise infecting agents via specific receptors. Subsequently, these agents are destroyed by degrading enzymes and fragments of the phagocytosed material are presented on the surface of the monocytes allowing lymphocytes to recognise them and initiate the adaptive immune response [5]. Furthermore, monocytes produce a variety of different pro-inflammatory mediators, such as interleukin (IL)-1, tumor necrosis factor alfa (TNFα) and different eicosanoids, which may act stimulating in an autocrine or paracrine way or act as recruiters of other cells important for the inflammatory response [6]. Monocytes expressing large amounts of CD14 but not CD16 on their surface are referred to as classical monocytes. The non-classical monocytes, which are CD14 as well as CD16 positive, are known as highly pro-inflammatory and represent, under normal conditions, about 10 % of the peripheral blood monocytes [7]. However, the amount of these cells can increase dramatically during inflammation. Monocytes have also been ascribed a role in the resolution of inflammation by producing for example anti-inflammatory mediators such as IL-10 [8]. This is highly important although inflammation is our essential defense against pathogens, if not tightly regulated, this defense can become our enemy. Chronic inflammation is a part of the cause for several more or less severe diseases, where elevated levels of the enzymes involved in the 1 arachidonic acid (AA) cascade as well as the produced metabolites, the eicosanoids, have been detected. Arachidonic acid and eicosanoids AA (20:4n-6; AA)
Recommended publications
  • Diclofenac Enhances Docosahexaenoic Acid-Induced Apoptosis in Vitro in Lung Cancer Cells
    cancers Article Diclofenac Enhances Docosahexaenoic Acid-Induced Apoptosis in Vitro in Lung Cancer Cells Rosemary A. Poku 1, Kylee J. Jones 2, Megan Van Baren 2 , Jamie K. Alan 3 and Felix Amissah 2,* 1 Department of Foundational Sciences, College of Medicine, Central Michigan University, Warriner Hall, 319, Mt Pleasant, MI 48859, USA; [email protected] 2 Department of Pharmaceutical Sciences, Ferris State University, College of Pharmacy, 220 Ferris Dr, Big Rapids, MI 49307, USA; [email protected] (K.J.J.); [email protected] (M.V.B.) 3 Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-231-591-3790 Received: 9 September 2020; Accepted: 17 September 2020; Published: 20 September 2020 Simple Summary: Polyunsaturated fatty acids (PUFAs) and non-steroidal anti-inflammatory drugs (NSAIDs) have limited anticancer capacities when used alone. We examined whether combining NSAIDs with docosahexaenoic (DHA) would increase their anticancer activity on lung cancer cell lines. Our results indicate that combining DHA and NSAIDs increased their anticancer activities by altering the expression of critical proteins in the RAS/MEK/ERK and PI3K/Akt pathways. The data suggest that DHA combined with low dose diclofenac provides more significant anticancer potential, which can be further developed for chemoprevention and adjunct therapy in lung cancer. Abstract: Polyunsaturated fatty acids (PUFAs) and non-steroidal anti-inflammatory drugs (NSAIDs) show anticancer activities through diverse molecular mechanisms. However, the anticancer capacities of either PUFAs or NSAIDs alone is limited. We examined whether combining NSAIDs with docosahexaenoic (DHA), commonly derived from fish oils, would possibly synergize their anticancer activity.
    [Show full text]
  • Prostaglandin E2 Deficiency Uncovers a Dominant Role for Thromboxane A2
    Prostaglandin E2 deficiency uncovers a dominant role for thromboxane A2 in house dust mite-induced allergic pulmonary inflammation Tao Liua,b, Tanya M. Laidlawa,b,c, Chunli Fenga,b, Wei Xinga,b, Shiliang Shena,b, Ginger L. Milned, and Joshua A. Boycea,b,c,1 Departments of aMedicine and cPediatrics, Harvard Medical School, Boston, MA 02115; bDivision of Rheumatology, Immunology, and Allergy, Jeff and Penny Vinik Center for Allergic Disease Research, Brigham and Women’s Hospital, Boston, MA 02115; and dDepartment of Pharmacology, Vanderbilt University, Nashville, TN 37232 Edited* by K. Frank Austen, Brigham and Women’s Hospital, Boston, MA, and approved June 20, 2012 (received for review May 10, 2012) fl – Prostaglandin E2 (PGE2) is an abundant lipid in ammatory media- PGE2 production (16 19) and reduced expression of the EP2 re- tor with potent but incompletely understood anti-inflammatory ceptor (20, 21), as well as marked tissue eosinophilia and bron- actions in the lung. Deficient PGE2 generation in the lung predis- choconstrictive responses to the administration of nonselective poses to airway hyperresponsiveness and aspirin intolerance in COX inhibitors. These findings suggest potential therapeutic fi −/− asthmatic individuals. PGE2-de cient ptges mice develop exag- applications of PGE2 in asthma and AERD if the mechanisms gerated pulmonary eosinophilia and pulmonary arteriolar smooth- responsible for the homeostatic functions of PGE2 in asthma can fi muscle hyperplasia compared with PGE2-suf cient controls when be fully defined. challenged intranasally with a house dust mite extract. We now An extract (Df) of the house dust mite Dermatophagoides demonstrate that both pulmonary eosinophilia and vascular farinae contains clinically relevant protease allergens, as well as fi remodeling in the setting of PGE2 de ciency depend on thrombox- adjuvants (glycans, endotoxin) that elicit sensitization through ane A2 and signaling through the T prostanoid (TP) receptor.
    [Show full text]
  • Coexpression of Microsomal Prostaglandin E Synthase With
    Coexpression of Microsomal Prostaglandin E Synthase with Cyclooxygenase-2 in Human Rheumatoid Synovial Cells FUMIAKI KOJIMA, HIROAKI NARABA, YASUHARU SASAKI, RENZO OKAMOTO, TOMIHISA KOSHINO, and SHINICHI KAWAI ABSTRACT. Objective. Recently, microsomal prostaglandin (PG) E synthase (mPGES) was cloned as a terminal enzyme catalyzing PGH2 to PGE2. We investigated mPGES as well as cyclooxygenase (COX)-2, catalyzing arachidonic acid to PGH2, in synovial cells from patients with rheumatoid arthritis (RA). The effect of dexamethasone on mPGES expression was also studied. Methods. Synovial cells were treated with interleukin 1ß (IL-1ß) and dexamethasone under various conditions, and expression of mPGES mRNA and protein was analyzed by Northern blot and Western blot, respectively. Conversions of arachidonic acid or PGH2 to PGE2 were measured by ELISA. Subcellular localization of mPGES and COX-2 was determined by immunofluorescent microscopic analysis. Results. mPGES mRNA and protein expression were significantly upregulated by IL-1ß in synovial cells. COX-2 mRNA and protein were also upregulated by IL-1ß, but with a different time course from that of mPGES. Conversion of PGH2 to PGE2 was increased by IL-1ß and was correlated with mPGES expression. Increased conversion of arachidonic acid to PGE2 was maintained when mPGES and COX-2 were coexpressed. Subcellular localization of mPGES and COX-2 overlapped in the perinuclear region in IL-1ß stimulated synovial cells. Dexamethasone inhibited mRNA and protein expression for mPGES and increased conversion of arachidonic acid to PGE2, but inhibition of mPGES was weaker compared with that of COX-2 in IL-1ß stimulated cells. Conclusion. The results suggest that abundant PGE2 production at inflammation sites such as rheumatoid synovia is caused by the coordinated upregulation of mPGES and COX-2.
    [Show full text]
  • Expression and Regulation of Microsomal Prostaglandin E Synthase
    Expression and Regulation of Microsomal Prostaglandin E Synthase-1 in Human Osteoarthritic Cartilage and Chondrocytes XINFANG LI, HASSAN AFIF, SARANETTE CHENG, JOHANNE MARTEL-PELLETIER, JEAN-PIERRE PELLETIER, PIERRE RANGER, and HASSAN FAHMI ABSTRACT. Objective. Elevated production of prostaglandin E2 (PGE2) plays an important role in the pathogen- esis of arthritis. Recently, an inducible microsomal prostaglandin E synthase-1 (mPGES-1) was identified. This enzyme is functionally coupled with cyclooxygenase-2 (COX-2) and converts the COX product PGH2 to PGE2. We analyzed expression of mPGES-1 in human normal and osteoarthritic (OA) cartilage and determined the effect of different inflammatory agonists on the expression of mPGES-1 in OA chondrocytes. Methods. Expression of mPGES-1 mRNA and protein in cartilage was determined by quantitative real-time reverse transcriptase-polymerase chain reaction and immunohistochemistry, respectively. OA chondrocytes were treated with different inflammatory agents, and mPGES-1 protein expression was evaluated by Western blot. Activation of the mPGES-1 promoter was assessed in transient trans- fection experiments. Results. Levels of mPGES-1 mRNA and protein were markedly elevated in OA versus normal car- tilage. Treatment of chondrocytes with interleukin 1ß (IL-1ß) induced expression of mPGES-1 pro- tein in a dose- and time-dependent manner. This appears to occur at the transcriptional level, as IL- 1ß induced expression of mPGES-1 mRNA and the activity of this gene promoter. Tumor necrosis factor-α (TNF-α) and IL-17 also upregulated expression of mPGES-1 protein and displayed a syn- ergistic effect with IL-1ß. Peroxisome proliferator-activated receptor-γ ligands, 15-deoxy-∆12,14- prostaglandin J2 and troglitazone, inhibited IL-1ß-induced mPGES-1 protein expression, an effect that was reversed by exogenous PGE2.
    [Show full text]
  • Structure-Based Discovery of Mpges-1 Inhibitors Suitable For
    www.nature.com/scientificreports OPEN Structure-based discovery of mPGES-1 inhibitors suitable for preclinical testing in wild-type Received: 4 January 2018 Accepted: 9 March 2018 mice as a new generation of anti- Published: xx xx xxxx infammatory drugs Kai Ding1,2,3, Ziyuan Zhou1,2, Shurong Hou2, Yaxia Yuan1,2,4, Shuo Zhou1,2, Xirong Zheng2, Jianzhong Chen1,2, Charles Loftin2, Fang Zheng1,2 & Chang-Guo Zhan1,2,4 Human mPGES-1 is recognized as a promising target for next generation of anti-infammatory drugs without the side efects of currently available anti-infammatory drugs, and various inhibitors have been reported in the literature. However, none of the reported potent inhibitors of human mPGES-1 has shown to be also a potent inhibitor of mouse or rat mPGES-1, which prevents using the well-established mouse/rat models of infammation-related diseases for preclinical studies. Hence, despite of extensive eforts to design and discover various human mPGES-1 inhibitors, the promise of mPGES-1 as a target for the next generation of anti-infammatory drugs has never been demonstrated in any wild-type mouse/rat model using an mPGES-1 inhibitor. Here we report discovery of a novel type of selective mPGES-1 inhibitors potent for both human and mouse mPGES-1 enzymes through structure-based rational design. Based on in vivo studies using wild-type mice, the lead compound is indeed non-toxic, orally bioavailable, and more potent in decreasing the PGE2 (an infammatory marker) levels compared to the currently available drug celecoxib. This is the frst demonstration in wild-type mice that mPGES-1 is truly a promising target for the next generation of anti-infammatory drugs.
    [Show full text]
  • Antiluteogenic Effects of Serial Prostaglandin F2α Administration in Mares
    ANTILUTEOGENIC EFFECTS OF SERIAL PROSTAGLANDIN F2α ADMINISTRATION IN MARES Thesis Presented in partial fulfillment of the requirements for the Master of Science in the Graduate School of The Ohio State University Elizabeth Ann Coffman Graduate ProGram in Comparative and Veterinary Medicine The Ohio State University 2013 Thesis committee: Carlos R.F. Pinto PhD, MV, DACT; Dissertation Advisor Marco A. Coutinho da Silva PhD, MV, DACT; Academic Advisor Christopher Premanandan PhD, DVM, DACVP Copyright by Elizabeth Ann Coffman 2013 Abstract For breedinG manaGement and estrus synchronization, prostaGlandin F2α (PGF) is one of the most commonly utilized hormones to pharmacologically manipulate the equine estrous cycle. There is a general supposition a sinGle dose of PGF does not consistently induce luteolysis in the equine corpus luteum (CL) until at least five to six days after ovulation. This leads to the erroneous assumption that the early CL (before day five after ovulation) is refractory to the luteolytic effects of PGF. An experiment was desiGned to test the hypotheses that serial administration of PGF in early diestrus would induce a return to estrus similar to mares treated with a sinGle injection in mid diestrus, and fertility of the induced estrus for the two treatment groups would not differ. The specific objectives of the study were to evaluate the effects of early diestrus treatment by: 1) assessing the luteal function as reflected by hormone profile for concentration of plasma progesterone; 2) determininG the duration of interovulatory and treatment to ovulation intervals; 3) comparing of the number of pregnant mares at 14 days post- ovulation. The study consisted of a balanced crossover desiGn in which reproductively normal Quarter horse mares (n=10) were exposed to two treatments ii on consecutive reproductive cycles.
    [Show full text]
  • Role of Arachidonic Acid and Its Metabolites in the Biological and Clinical Manifestations of Idiopathic Nephrotic Syndrome
    International Journal of Molecular Sciences Review Role of Arachidonic Acid and Its Metabolites in the Biological and Clinical Manifestations of Idiopathic Nephrotic Syndrome Stefano Turolo 1,* , Alberto Edefonti 1 , Alessandra Mazzocchi 2, Marie Louise Syren 2, William Morello 1, Carlo Agostoni 2,3 and Giovanni Montini 1,2 1 Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, Pediatric Nephrology, Dialysis and Transplant Unit, Via della Commenda 9, 20122 Milan, Italy; [email protected] (A.E.); [email protected] (W.M.); [email protected] (G.M.) 2 Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; [email protected] (A.M.); [email protected] (M.L.S.); [email protected] (C.A.) 3 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Pediatric Intermediate Care Unit, 20122 Milan, Italy * Correspondence: [email protected] Abstract: Studies concerning the role of arachidonic acid (AA) and its metabolites in kidney disease are scarce, and this applies in particular to idiopathic nephrotic syndrome (INS). INS is one of the most frequent glomerular diseases in childhood; it is characterized by T-lymphocyte dysfunction, alterations of pro- and anti-coagulant factor levels, and increased platelet count and aggregation, leading to thrombophilia. AA and its metabolites are involved in several biological processes. Herein, Citation: Turolo, S.; Edefonti, A.; we describe the main fields where they may play a significant role, particularly as it pertains to their Mazzocchi, A.; Syren, M.L.; effects on the kidney and the mechanisms underlying INS. AA and its metabolites influence cell Morello, W.; Agostoni, C.; Montini, G.
    [Show full text]
  • Downloaded from Bioscientifica.Com at 09/25/2021 12:14:58PM Via Free Access
    ID: 19-0149 8 6 Q Pang et al. PHO patients with soft tissue 8:6 736–744 giant tumor caused by HPGD mutation RESEARCH The first case of primary hypertrophic osteoarthropathy with soft tissue giant tumors caused by HPGD loss-of-function mutation Qianqian Pang1,2, Yuping Xu1,3, Xuan Qi1, Yan Jiang1, Ou Wang1, Mei Li1, Xiaoping Xing1, Ling Qin2 and Weibo Xia1 1Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China 2Musculoskeletal Research Laboratory and Bone Quality and Health Assessment Centre, Department of Orthopedics & Traumatology, The Chinese University of Hong Kong, Hong Kong SAR, Hong Kong 3Department of Endocrinology, The First Affiliated Hospital of Shanxi Medicalniversity, U Taiyuan, Shanxi, China Correspondence should be addressed to L Qin or W Xia: [email protected] or [email protected] Abstract Background: Primary hypertrophic osteoarthropathy (PHO) is a rare genetic multi-organic Key Words disease characterized by digital clubbing, periostosis and pachydermia. Two genes, f primary hypertrophic HPGD and SLCO2A1, which encodes 15-hydroxyprostaglandin dehydrogenase (15-PGDH) osteoarthropathy and prostaglandin transporter (PGT), respectively, have been reported to be related to f PHO PHO. Deficiency of aforementioned two genes leads to failure of prostaglandin E2 (PGE2) f HPGD mutation degradation and thereby elevated levels of PGE2. PGE2 plays an important role in f soft tumor tumorigenesis. Studies revealed a tumor suppressor activity of 15-PGDH in tumors, such f COX2 selective inhibitor treatment as lung, bladder and breast cancers. However, to date, no HPGD-mutated PHO patients presenting concomitant tumor has been documented.
    [Show full text]
  • Cyclooxygenase-Independent Inhibition by Aspirin
    Proc. Natl. Acad. Sci. USA Vol. 93, pp. 11091-11096, October 1996 Medical Sciences Leukocyte lipid body formation and eicosanoid generation: Cyclooxygenase-independent inhibition by aspirin (nonsteroidal antiinflammatory agents/cyclooxygenase knockout/leukotrienes/prostaglandin endoperoxide H synthase/lipoxygenase) PATRICIA T. BOZZA*, JENNIFER L. PAYNE*, ScoTr G. MORHAMt, ROBERT LANGENBACHt, OLIVER SMITHIESt, AND PETER F. WELLER*§ *Harvard Thorndike Laboratory and Charles A. Dana Research Institute, Department of Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA 02215-5491; tDepartment of Pathology, University of North Carolina, Chapel Hill, NC 27599-7525; and *Laboratory of Experimental Carcinogenesis and Mutagenesis, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709 Communicated by Seymour J. Klenbanoff, University of Washington School of Medicine, Seattle, WA, July 31, 1996 (received for review April 8, 1996) ABSTRACT Lipid bodies, cytoplasmic inclusions that de- inducible structures. Lipid bodies are prominent in leukocytes velop in cells associated with inflammation, are inducible at sites of natural and experimental inflammation, including structures that might participate in generating inflammatory leukocytes from joints of patients with inflammatory arthritis eicosanoids. Cis-unsaturated fatty acids (arachidonic and (5-7), the airways of patients with acute respiratory distress oleic acids) rapidly induced lipid body formation in leuko- syndrome (8), and casein- or lipopolysaccharide-elicited cytes, and this lipid body induction was inhibited by aspirin guinea pig peritoneal exudates (9). The formation of lipid and nonsteroidal antiinflammatory drugs (NSAIDs). Several bodies is a regulated process that involves activation of intra- findings indicated that the inhibitory effect of aspirin and cellular signaling pathways, including protein kinase C and NSAIDs on lipid body formation was independent of cycloox- phospholipase C (10, 11).
    [Show full text]
  • Effect of Prostanoids on Human Platelet Function: an Overview
    International Journal of Molecular Sciences Review Effect of Prostanoids on Human Platelet Function: An Overview Steffen Braune, Jan-Heiner Küpper and Friedrich Jung * Institute of Biotechnology, Molecular Cell Biology, Brandenburg University of Technology, 01968 Senftenberg, Germany; steff[email protected] (S.B.); [email protected] (J.-H.K.) * Correspondence: [email protected] Received: 23 October 2020; Accepted: 23 November 2020; Published: 27 November 2020 Abstract: Prostanoids are bioactive lipid mediators and take part in many physiological and pathophysiological processes in practically every organ, tissue and cell, including the vascular, renal, gastrointestinal and reproductive systems. In this review, we focus on their influence on platelets, which are key elements in thrombosis and hemostasis. The function of platelets is influenced by mediators in the blood and the vascular wall. Activated platelets aggregate and release bioactive substances, thereby activating further neighbored platelets, which finally can lead to the formation of thrombi. Prostanoids regulate the function of blood platelets by both activating or inhibiting and so are involved in hemostasis. Each prostanoid has a unique activity profile and, thus, a specific profile of action. This article reviews the effects of the following prostanoids: prostaglandin-D2 (PGD2), prostaglandin-E1, -E2 and E3 (PGE1, PGE2, PGE3), prostaglandin F2α (PGF2α), prostacyclin (PGI2) and thromboxane-A2 (TXA2) on platelet activation and aggregation via their respective receptors. Keywords: prostacyclin; thromboxane; prostaglandin; platelets 1. Introduction Hemostasis is a complex process that requires the interplay of multiple physiological pathways. Cellular and molecular mechanisms interact to stop bleedings of injured blood vessels or to seal denuded sub-endothelium with localized clot formation (Figure1).
    [Show full text]
  • Prostaglandin Signaling Regulates Nephron Segment Patterning Of
    RESEARCH ARTICLE Prostaglandin signaling regulates nephron segment patterning of renal progenitors during zebrafish kidney development Shahram Jevin Poureetezadi1,2, Christina N Cheng1,2, Joseph M Chambers1,2, Bridgette E Drummond1,2, Rebecca A Wingert1,2* 1Department of Biological Sciences, University of Notre Dame, Notre Dame, United States; 2Center for Stem Cells and Regenerative Medicine, Center for Zebrafish Research, University of Notre Dame, Notre Dame, United States Abstract Kidney formation involves patterning events that induce renal progenitors to form nephrons with an intricate composition of multiple segments. Here, we performed a chemical genetic screen using zebrafish and discovered that prostaglandins, lipid mediators involved in many physiological functions, influenced pronephros segmentation. Modulating levels of prostaglandin E2 (PGE2) or PGB2 restricted distal segment formation and expanded a proximal segment lineage. Perturbation of prostaglandin synthesis by manipulating Cox1 or Cox2 activity altered distal segment formation and was rescued by exogenous PGE2. Disruption of the PGE2 receptors Ptger2a and Ptger4a similarly affected the distal segments. Further, changes in Cox activity or irx3b sim1a PGE2 levels affected expression of the transcription factors and that mitigate pronephros segment patterning. These findings show for the first time that PGE2 is a regulator of nephron formation in the zebrafish embryonic kidney, thus revealing that prostaglandin signaling may have implications for renal birth defects and other diseases. DOI: 10.7554/eLife.17551.001 *For correspondence: rwingert@ nd.edu Introduction Competing interests: The The kidney serves central functions in metabolic waste excretion, osmoregulation, and electrolyte authors declare that no homeostasis. Vertebrate kidney organogenesis is a dynamic process involving the generation of up competing interests exist.
    [Show full text]
  • Medical Management of First-Trimester Induced Abortion and Miscarriage
    PACE REVIEW Medical management of first-trimester induced abortion and miscarriage Shamim Amis Jonathon Evans-Jones MRCOG FKCOG urgical evacuation is the mainstay of treatment in the effects of bleeding per vaginum, diarrhoea and vomiting. In UK for first-trimester termination of pregnancy and a randomised trial, where 1 mg versus 0.5 mg of gemeprost Smiscarriage and, although a niinor procedure, it has an was compared, the complete abortion rate was similar for associated considerable morbidity and mortality.' Induced the two groups (98-100%), although the incidence of abortion in the UK is now a safe procedure but on a global adverse effects was significantly lower in the latter group.'O scale continues to be a major cause of maternal mortality.2 Misoprosto1 is a synthetic analogue of prostaglandin E, and Medical management would provide a safe and effective causes increased uterine contractility with a low incidence of alternative. Many women would prefer to be given the other unwanted effects." The main advantages over choice and avoid the risks associated with anaesthesia and gemeprost are that it does not require refngeration, is cheaper surgery.l Recent studies have confirmed high acceptability and can be administered orally or vaginally. One gemeprost rates, showing that 8496% of women would choose pessary costs &22, whereas the equivalent dose of misoprostol medical treatment for a subsequent abortion." is just over The uterotonic properties are enkanced if women are pretreated with rmfepristone, reflecting the effect BACKGROUND of antiprogesterones in increasing sensitivity to prostaglandins. The drugs used for medically induced abortion in the UK When misoprostol is used in combination with mifepristone, include an antiprogesterone,mifepristone, and several prost- the vaginal route has been shown to be superior to the onl aglandin analogues, including gemeprost and misoprostol.
    [Show full text]